We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

42 hedge funds and large institutions have $3.1M invested in MiNK Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 2

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

250% more funds holding

Funds holding: 12 → 42 (+30)

169% more capital invested

Capital invested by funds: $1.15M → $3.1M (+$1.95M)

0.25% more ownership

Funds ownership: 0.18% → 0.43% (+0.25%)

Holders
42
Holders Change
+30
Holders Change %
+250%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
9
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$651K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$385K
3
Renaissance Technologies
Renaissance Technologies
New York
+$271K
4
BlackRock
BlackRock
New York
+$143K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$135K

Top Sellers

Rank Fund Capital Flow
1
LF
Longbow Finance
Switzerland
-$316K
2
AG
Artal Group
Luxembourg
-$123K
3
JMPWA
JP Morgan Private Wealth Advisors
California
-$61.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
DTC
1
Deep Track Capital
Connecticut
$682K +$651K +32,487 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$506K +$385K +19,207 +391%
AG
3
Artal Group
Luxembourg
$479K -$123K -6,137 -21%
Renaissance Technologies
4
Renaissance Technologies
New York
$306K +$271K +13,523 +1,313%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$195K +$135K +6,742 +266%
BlackRock
6
BlackRock
New York
$172K +$143K +7,117 +655%
Citadel Advisors
7
Citadel Advisors
Florida
$107K +$102K +5,105 New
OIM
8
Oracle Investment Management
Connecticut
$106K +$101K +5,046 New
CAPTRUST Financial Advisors
9
CAPTRUST Financial Advisors
North Carolina
$83K +$79.2K +3,954 New
State Street
10
State Street
Massachusetts
$60.4K +$35.4K +1,766 +159%
Wells Fargo
11
Wells Fargo
California
$57.6K +$54.9K +2,739 +91,300%
Bank of America
12
Bank of America
North Carolina
$55.3K +$52.8K +2,636 New
UOC
13
UBS O'Connor
Illinois
$45.3K +$43.3K +2,159 New
Goldman Sachs
14
Goldman Sachs
New York
$35.7K +$34.1K +1,701 New
HighTower Advisors
15
HighTower Advisors
Illinois
$30K +$13.2K +658 +63%
VF
16
Virtu Financial
New York
$30K +$28.5K +1,423 New
Morgan Stanley
17
Morgan Stanley
New York
$25.6K +$24.4K +1,219 New
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$24.2K +$23.1K +1,154 New
TRCT
19
Tower Research Capital (TRC)
New York
$23.4K +$22.3K +1,115 New
Northern Trust
20
Northern Trust
Illinois
$23.4K +$22.3K +1,113 New
Fidelity Investments
21
Fidelity Investments
Massachusetts
$19.9K +$19K +949 New
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$10.6K +$10.2K +507 New
UBS Group
23
UBS Group
Switzerland
$6.62K +$2.6K +130 +70%
FCB
24
First Command Bank
Texas
$2.17K +$2.06K +103 New
FCFS
25
First Command Financial Services
Texas
$2.17K +$2.06K +103 New
1
2

INKT Hedge Fund Activity: Q2 2023 in Review

42 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q2 2023, worth a combined $3.1M — up 169% from $1.15M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new INKT positions and 2 closed out — a net gain of 30 holders — while 9 added to existing stakes and 1 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $651K. The largest seller was Longbow Finance, exiting entirely with an estimated $316K sold.

  • 42 institutional investors held MiNK Therapeutics (INKT) as of Q2 2023, up from 12 in Q1 2023.
  • Funds reported $3.1M of MiNK Therapeutics stock for Q2 2023, up 169% quarter-over-quarter.
  • 32 funds opened new MiNK Therapeutics positions in Q2 2023 and 2 closed out, a net change of +30 holders.
  • The largest MiNK Therapeutics buyer in Q2 2023 was Deep Track Capital, an estimated $651K added.
  • The largest MiNK Therapeutics seller in Q2 2023 was Longbow Finance, an estimated $316K sold.

Based on aggregated 13F filings for Q2 2023.